|
Session 11
Oral Abstracts
Issues in Prevention of HIV Transmission and ART
Monday, 10 am - 12 noon
Room: Room 515 |
| 10:00 am 29 |
Pre-exposure Prophylaxis in Macaques against Rectal SIV Challenge by Mucosally Applied PMPA: Potential for Complementation of Microbicide and Vaccination Strategies
Martin Cranage*1, S Sharpe2, A Cope1, C Herrera1, M Dennis2, N Berry3, C Ham3, P Anton4, I McGowan4, and R Shattock1
1St George's, Univ of London, UK; 2Hlth Protection Agency, Porton Down, UK; 3Natl Inst for Biological Standards and Control, South Mimms, UK; and 4David Geffen Sch of Med, Univ of California, Los Angeles, US |
| 10:15 am 30 |
The Effect of Suppressive Acyclovir Therapy on HIV Cervicovaginal Shedding in HIV- and HSV-2-infected Women, Chiang Rai, Thailand
Eileen Dunne*1, S Whitehead1,2, S Whitehead1,2, M Sternberg1, S Thep-Amnuay2, W Leelawiwat2, J McNicholl1,2, J McNicholl1,2, S Sumanapun3, J Tappero1,2, J Tappero1,2, T Siriprapasiri4, and L Markowitz1
1CDC, Atlanta, GA, US; 2Thailand Ministry of Publ Hlth-CDC Collaboration, Nonthaburi and Chiang Rai Provincial Publ Hlth Office; 3Chiang Rai Provincial Publ Hlth Office, Thailand; and 4Ministry of Publ Hlth, Nonthaburi, Thailand |
| 10:30 am 31 |
Chlamydial and Gonococcal Infection among Gay and Bisexual Men at the Time of HIV+ Test Result: Implications for Co-treatment, San Francisco, 2004-2006
Katherine Scott*, C Kent, K Ahrens, S Philip, and J Klausner
San Francisco Dept of Publ Hlth, CA, US |
| 10:45 am 32 |
Potential Effect of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-limited Settings
Ume Abbas*1, R Anderson2, and J Mellors1
1Univ of Pittsburgh, PA, US and 2Imperial Coll, London, UK |
| 11:00 am 33 |
Efavirenz- vs Nevirapine-based ART Regimens: Adherence and Virologic Outcomes
Jean Nachega*1, M Hislop2, D Dowdy1, L Regensberg2, R Chaisson1, and G Maartens3
1Johns Hopkins Univ, Baltimore, MD, US; 2Aid for AIDS Disease Mgmt Prgm, Cape Town, South Africa; and 3Univ of Cape Town, South Africa |
| 11:15 am 34 |
Determinants of Mortality among HIV-infected Individuals Receiving Home-based ART in Rural Uganda
David Moore*1,2, David Moore*1,2, C Yiannoutsos3, B Musick3, R Downing1, W Were1, R Degerman1, L Alexander1, and J Mermin1
1Global AIDS Prgm, CDC Uganda, Entebbe; 2BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; and 3Indiana Univ Sch of Med, Indianapolis, US |
11:30 am 35
 |
Outcomes of Adults Receiving Second-line ART in Médecins Sans Frontières-supported Projects in Resources-limited Countries
M Pujades1, Alexandra Calmy*2, D O'Brien3, P Humblet4, and MSF HIV/AIDS working group
1Epicentre, Paris, France; 2St Vincent's Hosp, Sydney, Australia; 3Médecins Sans Frontières, Amsterdam, The Netherlands; and 4Médecins sans Frontières, Brussels, Belgium |
| 11:45 am 36LB |
Efficacy of Kaletra-based Second-line ART in Cambodia
Laurent Ferradini*1, O Segeral2, J Nouhin3, S Leakhena1, O Vara2, A Dulioust2, E Nerrienet3, J F Delfraissy4, and the ARV Second Line Study Group of Cambodia
1Médecins Sans Frontières, Phnom Penh, Cambodia; 2Esther/Calmette Hosp, Phnom Penh, Cambodia; 3Pasteur Inst of Cambodia, Phnom Penh; and 4French Agency for AIDS Res, Paris, France |
|
